Cargando…

Scientific rationale for a higher dose of nusinersen

OBJECTIVE: The long‐term favorable safety profile of nusinersen provides an opportunity to consider a higher dose. We report on the relationships between nusinersen cerebrospinal fluid (CSF) exposure, biomarker levels, and clinical efficacy. METHODS: The analyses used data from the CS3A and ENDEAR s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finkel, Richard S., Ryan, Monique M., Pascual Pascual, Samuel Ignacio, Day, John W., Mercuri, Eugenio, De Vivo, Darryl C., Foster, Richard, Montes, Jacqueline, Gurgel‐Giannetti, Juliana, MacCannell, Drew, Berger, Zdenek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186144/ https://www.ncbi.nlm.nih.gov/pubmed/35567345 http://dx.doi.org/10.1002/acn3.51562

Ejemplares similares

DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results
por: Finkel, Richard S., et al.
Publicado: (2023)

Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model
por: MacCannell, Drew, et al.
Publicado: (2022)

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function †
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
por: Coratti, Giorgia, et al.
Publicado: (2021)

RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design
por: Finkel, Richard S., et al.
Publicado: (2020)

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy
por: Chiriboga, Claudia A., et al.
Publicado: (2016)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
por: De Vivo, Darryl C., et al.
Publicado: (2019)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
por: Darras, Basil T., et al.
Publicado: (2019)

La era del signo : interpretación semiótica de la cultura moderna
por: MacCannell, Dean
Publicado: (1990)

Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-up
por: Barp, Andrea, et al.
Publicado: (2020)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
por: Pane, Marika, et al.
Publicado: (2022)

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients
por: Pane, Marika, et al.
Publicado: (2021)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy
por: Beaudin, Marie, et al.
Publicado: (2023)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec
por: Day, John W., et al.
Publicado: (2021)

SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
por: Kayadjanian, Nathalie, et al.
Publicado: (2013)

Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
por: Niazi, Sarfaraz
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_um6d065h502374krlt30g9fsfe